Optimizing Outcomes in Gastrointestinal Stromal Tumors: A Surgeon's Perspective

Area of Science:

• Gastroenterology
• Surgical Oncology
• Medical Oncology

Background:

• Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract.
• Tumor location significantly influences GIST presentation, prognosis, and treatment strategies.

Observation:

• Gastric GISTs generally present with a better prognosis compared to those in the small intestine or rectum.
• Tumor rupture during resection can lead to peritoneal spread and poorer outcomes.
• Minimally invasive surgery is suitable for smaller GISTs, while open surgery is necessary for larger or complex cases.

Findings:

• Complete surgical resection (R0) is the primary treatment for localized GISTs.
• Tyrosine kinase inhibitors (TKIs), such as imatinib, are vital for unresectable, metastatic, or high-risk GISTs.
• TKIs can be used as neoadjuvant or adjuvant therapy to improve surgical outcomes and reduce recurrence risk.

Implications:

• Tailoring treatment based on GIST location and risk factors is essential for optimizing patient survival.
• Adjuvant and neoadjuvant TKI therapy significantly impacts GIST management and recurrence rates.
• Long-term surveillance is critical for detecting late recurrences in GIST patients.